Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2014 | Original Paper

Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Authors: Oliver Ristow, Carlos Gerngroß, Markus Schwaiger, Bettina Hohlweg-Majert, Melanie Ristow, Steffen Koerdt, Roswitha Schuster, Sven Otto, Christoph Pautke

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2014

Abstract

Purpose

To find out whether the most popular pathogenesis hypothesis of the bisphosphonate (BP) related osteonecrosis of the jaw (BRONJ) is comprehensible: (1) is there a higher bone remodeling in the jaw compared with other skeletal sites? (2) Is the bone turnover (BT) of the jaw overly altered after BP intake? (3) Are there gender- or entity-specific differences in BT before and after BP intake?

Methods

Bone scintigraphies of 42 patients with prostate cancer were retrospectively analyzed (n = 21 with BP intake; n = 21 no BP). All patients received bone scintigraphy prior to the therapy and in the course of the treatment (after 12 and 24 months). Data were quantitatively analyzed using six predetermined regions of interest and compared with a breast cancer cohort.

Results

The mandible revealed a similar BT as the femur and a significant lower BT compared with the maxilla. All investigated bone regions showed no significant changes under BP administration. Inter-gender differences revealed significantly lower BT values for the prostate cancer compared with the female breast cancer cohort, changes over the course of time could not be found.

Conclusions

The finding that the mandible revealed a significant lower BT than the maxilla and the fact that 2/3 of the BRONJ cases occur in the mandible are inconsistent with the investigated hypothesis. Furthermore, the BT in the jawbone is not overly suppressed by BP. Thus, it seems implausible that a high BT and its over-suppression play the key role in the pathomechanism of BRONJ.

Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T (2008) “Bis-phossy jaws”—high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36(2):95–103. doi:10.1016/j.jcms.2007.06.008 PubMedCrossRef

Ackerman L, Shirazi P (1997) Abnormal skull uptake on bone scan. Semin Nucl Med 27(2):190–193PubMedCrossRef

Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68(5):959–963. doi:10.1016/j.joms.2009.10.010 PubMedCentralPubMedCrossRef

Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18(3):556–560. doi:10.1093/annonc/mdl408 PubMedCrossRef

Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70. doi:10.1016/j.joms.2009.01.007 PubMedCrossRef

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587. doi:10.1200/JCO.2005.02.8670 PubMedCrossRef

Bauss F, Pfister T, Papapoulos S (2008) Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26(4):406–408. doi:10.1007/s00774-007-0837-x PubMedCrossRef

Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342. doi:10.1038/nature01658 PubMedCrossRef

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583PubMedCrossRef

Garetto LP, Tricker ND (1998) Remodeling of bone surrounding the implant interface. In: Garetto LP, Turner CH, Duncan RL, Burr DB (eds) Bridging the gap between dental and orthopaedic implants. Indianapolis, IN

Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Min Res 12(4):498–508. doi:10.1359/jbmr.1997.12.4.498 CrossRef

Hansen PJ, Knitschke M, Draenert FG, Irle S, Neff A (2012) Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment-a grossly underestimated risk? Clin Oral Invest. doi:10.1007/s00784-012-0873-3

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F (2008) EAU guidelines on prostate cancer. Eur Urol 53(1):68–80. doi:10.1016/j.eururo.2007.09.002 PubMedCrossRef

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Mineral Res 23(6):826–836. doi:10.1359/jbmr.080205

Huja SS, Fernandez SA, Hill KJ, Li Y (2006) Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288(12):1243–1249. doi:10.1002/ar.a.20396 PubMedCentralPubMed

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol 52(5):1381–1387. doi:10.1016/j.eururo.2007.02.033 PubMed

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117PubMed

Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK (2010) Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clin Breast Cancer 10(1):33–39. doi:10.3816/CBC.2010.n.004 PubMed

Otto S, Hafner S, Grotz KA (2009) The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67(3):589–592. doi:10.1016/j.joms.2008.09.028 PubMed

Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, Sturzenbaum SR, von Tresckow E, Kolk A, Ehrenfeld M, Pautke C (2010) Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 68(5):1158–1161. doi:10.1016/j.joms.2009.07.079 PubMed

Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, Pautke C (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40(4):303–309. doi:10.1016/j.jcms.2011.05.003 PubMed

Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44(1):4–10. doi:10.1016/j.bone.2008.09.012 PubMed

Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41(3):318–320. doi:10.1016/j.bone.2007.04.196 PubMed

Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Otto S, Pautke C (2013) Is the bone turnover of the jawbone and its possible oversuppression by bisphosphonates of etiological importance for the pathogenesis of the bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg. doi:10.1016/j.joms.2013.11.005

Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A (2007) Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6(12 Pt 1):3256–3262. doi:10.1158/1535-7163.MCT-07-0311 PubMed

Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, Baumann P, Schmidmaier R, Bumeder I, Oduncu FS (2012) Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 35(11):658–664. doi:10.1159/000343950 PubMed

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB (2010) Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid. Oral Oncol 46(3):214–218. doi:10.1016/j.oraloncology.2010.01.001 PubMed

Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072. doi:10.1016/j.eururo.2008.06.070 PubMed

Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Invest 14(1):35–41. doi:10.1007/s00784-009-0266-4

Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D (2006) The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91(9):1165–1171PubMed

Title: Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
Authors: Oliver Ristow
Carlos Gerngroß
Markus Schwaiger
Bettina Hohlweg-Majert
Melanie Ristow
Steffen Koerdt
Roswitha Schuster
Sven Otto
Christoph Pautke
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1588-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers

Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer

Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma

High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer

Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials